Compare Stocks: MDXH, EQ, CNTB, and HURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.84	$2.28	$1.23 ▼ $3.82	$115.87M	-0.23	914,142 shs	2.41 million shs
EQ Equillium	$2.21	$2.48	$0.76 ▼ $3.54	$140.14M	1.81	431,500 shs	225,911 shs
HURA TuHURA Biosciences	$2.14	$2.22	$0.41 ▼ $3.43	$136.38M	-0.02	280,617 shs	367,762 shs
MDXH MDxHealth	$0.75	$0.54	$0.40 ▼ $5.33	$37.05M	1.57	17.68 million shs	270,087 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-17.49%	-16.36%	-16.36%	+5.14%
EQ Equillium	0.00%	-7.53%	+4.74%	-20.22%	+15.71%
HURA TuHURA Biosciences	0.00%	+1.42%	+0.47%	+4.65%	-16.08%
MDXH MDxHealth	0.00%	+3.84%	+62.34%	+37.07%	-78.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.84	$2.28	$1.23 ▼ $3.82	$115.87M	-0.23	914,142 shs	2.41 million shs
EQ Equillium	$2.21	$2.48	$0.76 ▼ $3.54	$140.14M	1.81	431,500 shs	225,911 shs
HURA TuHURA Biosciences	$2.14	$2.22	$0.41 ▼ $3.43	$136.38M	-0.02	280,617 shs	367,762 shs
MDXH MDxHealth	$0.75	$0.54	$0.40 ▼ $5.33	$37.05M	1.57	17.68 million shs	270,087 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-17.49%	-16.36%	-16.36%	+5.14%
EQ Equillium	0.00%	-7.53%	+4.74%	-20.22%	+15.71%
HURA TuHURA Biosciences	0.00%	+1.42%	+0.47%	+4.65%	-16.08%
MDXH MDxHealth	0.00%	+3.84%	+62.34%	+37.07%	-78.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	303.73% Upside
EQ Equillium	2.91	Moderate Buy	$7.57	242.60% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	320.56% Upside
MDXH MDxHealth	2.40	Hold	$2.17	189.51% Upside

Current Analyst Ratings Breakdown

Latest MDXH, EQ, CNTB, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	EQ Equillium	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
9/3/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $2.00
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$5.00 ➝ $3.00
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/11/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/21/2026	EQ Equillium	Clear Str Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	HURA TuHURA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	EQ Equillium	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
7/13/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$60K	1,931.08	N/A	N/A	$0.75 per share	2.45
EQ Equillium	$41.10M	3.41	N/A	N/A	$0.47 per share	4.70
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
MDXH MDxHealth	$107.88M	0.34	N/A	N/A	($0.24) per share	-3.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
EQ Equillium	-$22.40M	-$0.20	N/A	N/A	N/A	N/A	-41.15%	-38.29%	11/12/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A

Latest MDXH, EQ, CNTB, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	-$0.04	+$0.0140	-$0.04	N/A	N/A
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
EQ Equillium	N/A	23.40	23.40
HURA TuHURA Biosciences	0.20	0.18	0.18
MDXH MDxHealth	N/A	1.15	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
EQ Equillium	27.05%
HURA TuHURA Biosciences	0.62%
MDXH MDxHealth	N/A

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
EQ Equillium	17.84%
HURA TuHURA Biosciences	6.06%
MDXH MDxHealth	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable
EQ Equillium	40	63.41 million	52.10 million	Not Optionable
HURA TuHURA Biosciences	N/A	63.73 million	59.87 million	N/A
MDXH MDxHealth	300	49.50 million	48.66 million	Not Optionable

MDXH, EQ, CNTB, and HURA Headlines

Recent News About These Companies

MDxHealth Files 2026 Interim Report as Losses Deepen but Fresh Capital Extends Runway

September 3, 2026 | tipranks.com

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

August 21, 2026 | fool.com

3 Top Penny Stocks to Watch Today, 8/18/26

August 18, 2026 | tipranks.com

MDxHealth Soars to Record-Breaking Quarter with 14% Sequential Revenue Increase

August 17, 2026 | news.themarketisopen.comN

MDxHealth S.A. Q2 2026 Earnings Call Summary

August 15, 2026 | finance.yahoo.com

MDxHealth says well-positioned to 'return to positive EBITDA'

August 14, 2026 | msn.com

MDxHealth SA (MDXH) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2026 | zacks.com

MDxHealth Raises $20 Million in Direct Share Offering and Amends Articles After Capital Increase

August 13, 2026 | tipranks.com

Mdxhealth Reports Second Quarter 2026 Financial Results

August 13, 2026 | globenewswire.com

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13

July 30, 2026 | globenewswire.com

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed ...

July 24, 2026 | enidnews.comE

Mdxhealth SA receives Nasdaq non-compliance notice

July 24, 2026 | msn.com

mdxhealth Receives Nasdaq Notice of Minimum Market Value Deficiency

July 24, 2026 | quiverquant.comQ

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency

July 24, 2026 | globenewswire.com

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

July 2, 2026 | globenewswire.com

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT ...

June 29, 2026 | markets.businessinsider.com

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

June 29, 2026 | globenewswire.com

MDxHealth to Shut Down Resolve UTI Business

May 25, 2026 | ocbj.comO

MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MDXH, EQ, CNTB, and HURA Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.84 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Equillium NASDAQ:EQ

$2.21 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

TuHURA Biosciences NASDAQ:HURA

$2.14 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

MDxHealth NASDAQ:MDXH

$0.75 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXH, EQ, CNTB, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXH, EQ, CNTB, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXH, EQ, CNTB, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDXH, EQ, CNTB, and HURA Company Descriptions

Connect Biopharma NASDAQ:CNTB

Equillium NASDAQ:EQ

TuHURA Biosciences NASDAQ:HURA

MDxHealth NASDAQ:MDXH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXH, EQ, CNTB, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXH, EQ, CNTB, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXH, EQ, CNTB, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDXH, EQ, CNTB, and HURA Company Descriptions

Connect Biopharma NASDAQ:CNTB

Equillium NASDAQ:EQ

TuHURA Biosciences NASDAQ:HURA

MDxHealth NASDAQ:MDXH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools